Sunitinib and Surgery in Treating Patients With Localized or Metastatic Kidney Cancer
Completed · Not applicable
Conditions studied: Kidney Cancer
In brief
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving sunitinib before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. PURPOSE: This clinical trial is studying the side effects of giving sunitinib before surgery and to see how well it works in treating patients with localized or metastatic kidney cancer.
Key facts
- Study ID
- NCT00849186
- Run by
- Roswell Park Cancer Institute
- People needed
- 20
- Starts
- 2007-08-01
- Expected to finish
- 2010-04-01
- Last updated by the study team
- 2015-02-06
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Roswell Park Cancer Institute — Buffalo, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.